Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactulose effects on gut microbiota in healthy volunteers and irritable bowel syndrome subtypes
ChiCTR1900023211Phase 4Not yet recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lactulose in Diarrhea-predominant irritable bowel syndrome (IBS-D) and irritable bowel syndrome (IBS) (3 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Composition and diversity of gut microbiota. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
lactulose
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR1900023211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023211.